Volume 50, Issue 6 pp. 1213-1220
Research Article

Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: A follow-up of patients included in the childhood cancer registry of the Rhône-Alpes region in France (ARCERRA)

Fernand Freycon MD

Corresponding Author

Fernand Freycon MD

Childhood Cancer Registry of the Rhône-Alpes Region, Saint-Etienne, France

ARCERRA, 27 rue Emile Clermont, 42100 Saint-Etienne, France.===Search for more papers by this author
Béatrice Trombert-Paviot MD, PhD

Béatrice Trombert-Paviot MD, PhD

Department of Public Health and Medical Informatics, University of Saint Etienne, Saint-Etienne Cedex, France

Search for more papers by this author
Léonie Casagranda CRA

Léonie Casagranda CRA

Pediatric Hematology and Oncology Unit, Hôpital Nord, University of Saint-Etienne, Saint-Etienne Cedex 2, France

Search for more papers by this author
Yves Bertrand MD

Yves Bertrand MD

Pediatric Hematology and Bone Marrow Transplantation, Hôpital Debrousse, Lyon Cedex 05, France

Search for more papers by this author
Dominique Plantaz MD

Dominique Plantaz MD

Pediatric Hematology and Oncology Unit, Centre Hospitalo-Universitaire de Grenoble, Grenoble Cedex 09, France

Search for more papers by this author
Perrine Marec-Bérard MD

Perrine Marec-Bérard MD

Pediatric Oncology Unit, The Centre Léon Bérard, Lyon Cedex 08, France

Search for more papers by this author
First published: 25 February 2008
Citations: 25

Abstract

Background

We assessed the number and causes of treatment-related deaths (TRDs) in childhood cancer over time and correlated them with adherence to therapeutic guidelines.

Procedure

We compared two cohorts of children of the Childhood Cancer Registry of the Rhône-Alpes Region: Cohort I (1987–1992, 909 patients) and Cohort II (1996–1999, 648 patients).

Results

In all cancers together, 75 TRDs were reported in Cohort I and 24 in Cohort II (P = 0.001). Cumulative incidence at 5 years declined from 7.9% to 4.1%, and overall survival (OS) increased from 71.0% to 77.2%. TRDs declined by nearly 10-fold in patients with solid malignant tumors (P = 0.02) and central nervous system tumors (P = 0.001), but OS improved for patients with solid malignant tumors only (P = 0.01). No difference was observed in treatment- and transplantation-related deaths in patients with acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML), but OS was better in patients with AML (P = 0.02). Between the two cohorts, transplantation-related mortality did not decrease and was higher at 5 years in patients with ALL who received unrelated-matched donor transplants (41.3%) than in those receiving sibling-matched donor transplants (18.7%). OS improved in the respective transplant groups (37.0% and 64.2%). Severe graft-versus-host disease was also observed among patients with ALL (P = 0.036). The decrease in TRDs was correlated with compliance to therapeutic guidelines.

Conclusion

Although mortality declined, improved adherence to therapeutic guidelines and more restricted indications of allograft are needed to preclude further treatment- and transplantation-related deaths, particularly among those with leukemia. Pediatr Blood Cancer 2008;50:1213–1220. © 2008 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.